GIP and type 2 diabetes mellitus: The remaining 18 MS-PAVs were novel and included proteins that may be inaccessible to affinity-based proteomics, such as a variant in the incretin pro-peptide (Gastric Inhibitory Polypeptide, GIP) which plays a central role in type 2 diabetes and cardiovascular disease pathologies.